Discussion
Zevaskyn (prademagene zamikeracel), a gene therapy approved in the U.S. last year to treat the fragile skin disease recessive dystrophic epidermolysis bullosa (RDEB), can now be administered at University of Florida Health, a university-affiliated clinic in Gainesville. That’s according to Abeona Therapeutics, the company that markets Zevaskyn, which…